Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas

Last updated: August 26, 2024
Sponsor: Dartmouth-Hitchcock Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gliomas

Astrocytoma

Brain Cancer

Treatment

N/A

Clinical Study ID

NCT01849952
D12160
  • Ages > 18
  • All Genders

Study Summary

MicroRNAs (miRNA) are molecular biomarkers that post-transcriptionally control target genes. Deregulated miRNA expression has been observed in diverse cancers. In high grade gliomas, known as glioblastomas, the investigators have identified an oncogenic miRNA, miRNA-10b (mir-10b) that is expressed at higher levels in glioblastomas than in normal brain tissue. This study tests the hypothesis that in primary glioma samples mir-10b expression patterns will serve as a prognostic and diagnostic marker. This study will also characterize the phenotypic and genotypic diversity of glioma subclasses. Furthermore, considering the critical function of anti-mir-10b in blocking established glioblastoma growth, the investigators will test in vitro the sensitivity of individual primary tumors to anti-mir-10b treatment. Tumor, blood and cerebrospinal fluid samples will be obtained from patients diagnosed with gliomas over a period of two years. These samples will be examined for mir-10b expression levels. Patient survival, as well as tumor grade and genotypic variations will be correlated to mir-10b expression levels.

Eligibility Criteria

Inclusion

Inclusion/Exclusion Criteria:

  • 18 years of age

  • Brain tumor(s) to be resected for clinical reasons.

  • Histological pathology confirmation that tumor is of glial origin, WHO Grade II, III or IV.

  • Adequate tissue available for processing as determined by Pathology.

  • Adequate decision making ability to review, discuss and sign a consent form to allow their tumor samples to be used for future human brain tumor biology laboratory research. Determination of capacity to consent is made by one of the co-investigators based on clinical assessment.

  • Patients opting for the standard treatment regimen for their disease as well as ongoing clinical trials will be are eligible to participate in this study. Standard care for newly-diagnosed glioblastomas typically consists of surgical resection followed by radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide chemotherapy.

Study Design

Total Participants: 200
Study Start date:
October 09, 2013
Estimated Completion Date:
May 01, 2025

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

  • Tufts Medical Center

    Boston, Massachusetts 02111
    United States

    Site Not Available

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire 03756
    United States

    Active - Recruiting

  • University of Vermont

    Burlington, Vermont 05405
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.